Article
Hematology
Yao-jia Shen, Yi Zhang, Jie Chang, Hua-feng Wang, Xing-nong Ye, Li Zhu, Jie Jin, Hong-hu Zhu
Summary: The CAG regimen is effective in treating CBF-AML patients and reducing fusion transcript levels, resulting in improved molecular response rates.
ANNALS OF HEMATOLOGY
(2023)
Article
Oncology
Yan Wei, Lijun Wang, Chengying Zhu, Honghua Li, Jian Bo, Ran Zhang, Ning Lu, Yongli Wu, Xiaoning Gao, Liping Dou, Daihong Liu, Chunji Gao
Summary: Chemotherapy followed by donor lymphocyte infusion (DLI) is a promising treatment for patients with relapsed acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) after allogenic hematopoietic stem cell transplantation (allo-HSCT). The CCAG plus DLI regimen is safe and effective, and leads to durable remission and improved survival rates.
Article
Biochemistry & Molecular Biology
Bara'ah Khaleel, Eitan Lunenfeld, Joseph Kapelushnik, Mahmoud Huleihel
Summary: The combined treatment of GCSF and CYT in AML-diagnosed mice extends their survival and promotes sperm production without affecting testicular histology.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Jun-Feng Zhu, Hai-Ping Dai, Qian-Qian Zhang, Jia Yin, Zheng Li, Qin-Ya Cui, Xiao-Peng Tian, Si-Ning Liu, Zheng-Ming Jin, Xia-Ming Zhu, De-Pei Wu, Xiao-Wen Tang
Summary: In this retrospective study, the decitabine combined with HAAG regimen demonstrated effective and well-tolerated induction therapy in patients with newly diagnosed acute myeloid leukemia.
FRONTIERS IN ONCOLOGY
(2022)
Article
Hematology
Wenbing Duan, Sen Yang, Ting Zhao, Lijuan Hu, Yazhen Qin, Jinsong Jia, Jing Wang, Shengye Lu, Hao Jiang, Xiaohui Zhang, Lanping Xu, Yu Wang, Yueyun Lai, Hongxia Shi, Xiaojun Huang, Qian Jiang
Summary: This study compared the efficacy of HAA and IA regimens as first induction chemotherapy in CBF-AML patients. The results showed that the HAA regimen had better outcomes, with higher remission rate and more favorable relapse-free survival, for patients with RUNX1::RUXN1T1 gene abnormality. However, there was no difference in efficacy between the two regimens for patients with CBFB::MYH11 gene abnormality.
ANNALS OF HEMATOLOGY
(2023)
Article
Hematology
Takaaki Konuma, Jun Ooi, Hitomi Nagayama, Akira Tomonari, Nobuhiro Tsukada, Seiko Kato, Toshiro Kawakita, Masamichi Isobe, Maki Monna-Oiwa, Arinobu Tojo, Tohru Iseki, Satoshi Takahashi
Summary: This study followed 169 adult patients with myeloid malignancies who received myeloablative conditioning regimen involving G-CSF and high-dose cytarabine. The overall survival rate at 10 years was 62.5%, with a 26.0% relapse rate and a 16.9% non-relapse mortality rate. Higher disease risk index significantly increased overall mortality risk.
ANNALS OF HEMATOLOGY
(2022)
Article
Oncology
Baohang Zhang, Qingguo Liu, Junfan Li, Yimin Hu, Xin Zhao, Pingping Huang, Shangzhu Li, Ying Wang
Summary: In this study, a shortened 3-day cyclophosphamide and Ara-C regimen was used, with the addition of low-dose venetoclax (VEN), and the efficacy and safety were reported. The results showed that this regimen is highly effective in newly diagnosed AML patients and the addition of VEN achieves a higher and deeper one-course remission.
FRONTIERS IN ONCOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Atsushi Takamatsu, Kotaro Yoshida, Fumihito Toshima, Kazuto Kozaka, Naho Yamamoto, Yoshimichi Sai, Toshifumi Gabata
Summary: This study aims to clarify the incidence and clinicoradiologic characteristics of pegfilgrastim-induced aortitis. The results of the study found that the incidence of pegfilgrastim-induced aortitis may be higher than previously reported and may be more common in patients with esophageal cancer and those who received specific anticancer drugs. Furthermore, CT findings indicated that pegfilgrastim-induced aortitis is often characterized by involvement of the aortic arch and proximal branches.
Article
Medicine, Research & Experimental
Fan-cong Kong, Ling Qi, Yu-lan Zhou, Min Yu, Wen-feng Huang, Fei Li
Summary: This study retrospectively assessed the clinical data of R/R AML patients who received the CDCAG regimen and found that the regimen was effective and well-tolerated. Patients with DNMT3A, TET2, and IDH1/2 mutations might benefit from this regimen.
CURRENT MEDICAL SCIENCE
(2023)
Article
Oncology
Chong Wei, Yan Zhang, Wei Wang, Wei Zhang
Summary: Substituting PEG-rhG-CSF for short-acting rhG-CSF in the DA-EPOCH regimen significantly reduces the incidence of febrile neutropenia and related hospitalization, while simplifying management for both patients and healthcare providers.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Multidisciplinary Sciences
Kwai Han Yoo, Hyeoung-Joon Kim, Yoo Hong Min, Dae-Sik Hong, Won Sik Lee, Hee-Je Kim, Ho-Jin Shin, Yong Park, Je-Hwan Lee, Hawk Kim
Summary: Age influences the biology and clinical outcomes of AML patients, with a decrease in the proportion of favorable risk patients and those receiving induction chemotherapy as age increases. The rates of achieving complete response (CR) also decrease with age, particularly in patients over 60 years old.
Article
Medicine, General & Internal
Yosuke Dotsu, Hiroyuki Yamaguchi, Minoru Fukuda, Takayuki Suyama, Noritaka Honda, Yasuhiro Umeyama, Hirokazu Taniguchi, Hiroshi Gyotoku, Shinnosuke Takemoto, Ryuta Tagawa, Ryosuke Ogata, Hiromi Tomono, Midori Shimada, Hiroaki Senju, Katsumi Nakatomi, Seiji Nagashima, Hiroshi Soda, Hiroaki Ikeda, Kazuto Ashizawa, Hiroshi Mukae
Summary: This study examined the real-world incidence of febrile neutropenia among patients with thoracic malignancies treated with single-agent amrubicin chemotherapy, and found that the incidence rate was 30%. It suggests that prophylactic G-CSF should be administered during practical use of this chemotherapy regimen for patients who have already undergone chemotherapy.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
Vincenzo Adamo, Lorenzo Antonuzzo, Marco Danova, Michelino De Laurentiis, Paolo Marchetti, Carmine Pinto, Giovanni Rosti
Summary: This study aims to improve adherence to guideline recommendations for the prevention of febrile neutropenia and to enhance patient care.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Biochemistry & Molecular Biology
Yulia Michailov, Ali AbuMadighem, Eitan Lunenfeld, Joseph Kapelushnik, Mahmoud Huleihel
Summary: The study indicates that AML and CYT treatment have a significant negative impact on male fertility, but GCSF injection can improve this damage, restore spermatogenesis and fertility, showing potential value in preserving/restoring fertility in leukemia patients undergoing chemotherapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Anna Yeaton, Geraldine Cayanan, Sanam Loghavi, Igor Dolgalev, Emmett M. Leddin, Christian E. Loo, Hedieh Torabifard, Deedra Nicolet, Jingjing Wang, Kate Corrigan, Varvara Paraskevopoulou, Daniel T. Starczynowski, Eric Wang, Omar Abdel-Wahab, Aaron D. Viny, Richard M. Stone, John C. Byrd, Olga A. Guryanova, Rahul M. Kohli, G. Andres Cisneros, Aristotelis Tsirigos, Ann-Kathrin Eisfeld, Iannis Aifantis, Maria Guillamot
Summary: This article describes a novel animal model carrying a recurrent TET2 missense mutation frequently found in patients with CH and leukemia. Using single-cell transcriptomic profiling of the bone marrow, the study showed that disease progression in aged animals correlates with an enhanced inflammatory response and the emergence of an aberrant inflammatory monocytic cell population.
